Is there a drug for every disease?

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC's DG Enterprise and Industry in 2006, gives inventors the recognition they deserve. And, like every competition, it is an incentive to all other potential winners. It protects ideas and encourages innovation.

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC’s DG Enterprise and Industry in 2006, gives inventors the recognition they deserve.

Pharmaceutical firms in Europe have an awkward relation with their customers. The truth is that their selling prices and product licencing are directly or indirectly controlled by the buyers, that is governments, or government control health insurance schemes, offering almost free health services to citizens. As everybody knows governments are not only able to influence the approval of new drugs, they are also empowered with the ability to set prices by law.With healthcare costs skyrocketing over the past years and the fiscal crisis having engulfed almost all the 27 EU member states, governments have become very careful over their budgets and spending. In view of that, governments have at least two first hand possibilities, to cut down the drug bill.

For one thing officials can reject the use of new and expensive drugs on the grounds that they have no additional cure properties compared to existing formulas or generic medicines. Secondly, governments can set prices by law, or ask the pharmaceutical firms to return a part of their proceeds at the end of the year. As for the licencing procedure it is a common secret that it can be influenced by state officials.

In view of all that pharmaceutical companies are obliged on many occasions to retreat some of their drugs from entire countries, if the governments are not willing to pay what the firms demand. Another dreadful development is that the arbitrary settings of drug cost by governments, leads some times to huge price differences of the same drug, even in neighbouring countries. In this way large incentives for parallel exports are created, to the detriment of the maker.

Greece is an example of all that absurdities in the market of drags.

Greece

This debt stricken and practically bankrupt country has a history of high drug bills. Government spending on medicines skyrocketed within a few years, from 2002 to 2008. In this short time interval, state budget and public health schemes spending on medicines, doubled to €9 billion from less than €5bn. This outrageous development was the outcome of fraudulent behaviour all along the line. Doctors issued hideously expensive prescriptions, patients didn’t mind because they didn’t pay themselves and pharmacists had a guaranteed 30% profit on sales. During the same time period the number of pharmacies almost doubled and today their numbers per 100,000 of population are 60% above Belgium, the country with more pharmacies in the European Union.

As everybody remembers however, towards the end of 2009 Greece found difficulties in honouring its public debt and within months Eurozone had to support Athens, in order this Eurozone country to avoid bankruptcy. From then onwards Greece is under strong pressure to cut down government spending. To a large extend those fiscal deficit reductions are realised through deep cuts on public bills on drugs. Actually the Greek government doesn’t pay at all its drag bills for many months in a row, posing grave liquidity problems to makers, wholesalers and pharmacists.

The Greek authorities however are using more “methods” to cut down the drag bill. Successive Health Ministers had a rough time, trying to expand the use of generics. Expenditure on prototypes was 80% of total, while in Swiss home to many pharmaceutical giants, such generosity is out of question. In any case medicines are not the only bitter pills, Greece should take. A major reorganisation of the country’s health system was long overdue, but the government rushed to economise on the easy target, which is the expenditure on medicines.

Due to continued government inability to tackle the problem in a rational and organised way over the past months, the entire public health system of Greece is in a desperate state, with everybody going on strike and first degree health care and hospitals deep in the red.

Incidentally the abuse of prototype drags is responsible for only a small part of the huge debts the Greek health system accumulates every month. The Greek government owes billions of euros to many Pharmaceutical firms and some of them are threatening to abandon the country altogether and retreat their drags. Unfortunately there is no end to what is wrong with the Greek health system.

Mismanagement and corruption reigned for decades in public hospitals and the first degree health care system of the country, starting from the unholy alliance of doctors and pharmacists, to the exploitation of hospital patients by doctors. It is not clear which direction the whole issue will take, but it is more that certain a lot of things are to change. Probably the public healthcare system will shrink and the private sector will take its place.

But let Greece cure its own diseases and direct this discussion to the powerhouse of pharmaceutical industry, the R&D.

New drags

No need to say, that success in this department is key to survival and growth. Understandably, pharmaceutical firms can secure additional receipts and extra profits only from new drugs, the development and licencing of which though is becoming all the time more complicated and expensive. On top of that research and development of new formulas has become so focused and specialised, that on many occasions it is carried through more successfully by small groups or even one scientist in private laboratories or universities.

As a result major companies with big, expensive and sometimes rigid R&D departments cannot compete with independent researchers. Practice has shown that the solution the large multinationals now prefer is to buy out small research firms rather than develop new drags by themselves. Still however there are great risks and large investments are required.

“To help cope with declining revenue, Pfizer, Eli Lilly & Co., Bristol-Myers and AstraZeneca will probably increase spending on acquisitions beyond their normal budgets because of “deep operating challenges coupled with deep pockets,” Fitch Ratings said last week”, and Bloomberg reported.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Fighting cybercrime – what happens to the law when the law cannot be enforced?

EU leaders agree to delay Brexit until 31 October

InvestEU Fund: boost for sustainable, innovative and social investment

The Netherlands is paying people to cycle to work

“C’est la vie”? French recession and unemployment to linger in Eurozone

Health Committee MEPs back plans to boost joint assessment of medicines

Electronic Cigarettes: A booster or alternative to Smoking?

Here’s how to close the $176 billion health financing gap

Statistics show the ugly face of youth training schemes

Latvian economy is thriving, but boosting productivity, improving social protection and transitioning to a low-carbon productive model are vital for sustainable and inclusive growth

16 foods that are good for you – and the planet

More children killed by unsafe water, than bullets, says UNICEF chief

Is staying in the new going out? How the COVID-19 pandemic is fuelling the stay-at-home economy

“Access denied”: the Greek health system under pressure

Draghi’s negative interest rates help Eurozone’s cohesion

How speaking ‘parentese’ to your child could make them a faster learner

The role of medical students in promoting women’s rights

Help African farmers cope with climate change threats, UN food agency urges

MEPs back plans to halt spread of drug resistance from animals to humans

This AI is working with a fleet of drones to help us fight ocean plastic

Desires for national independence in Europe bound by economic realities

Strength in unity: Commission makes recommendations for the EU’s next strategic agenda 2019-2024

A Trumpist squad shook Davos and the world

Eurozone’s bank resolution mechanism takes a blow

Visa facilitation and readmission: agreements with Belarus now in force

Bringing nuclear test ban treaty into force a ‘central pillar’ of global disarmament push, says UN chief

End fossil fuel subsidies, and stop using taxpayers’ money to destroy the world: Guterres

France sneaks into the Geneva US-Iran talks to claim its business share in Tehran

Four major resources for new European young entrepreneurs

This air taxi uses 5G to ‘see’ around corners

Reforms in Lithuania are reinforcing economic growth but boosting productivity is still a challenge

Parenting in the time of COVID-19? Consider these 6 tips from the WHO

‘Air bridge’ vaccination operation begins for Ebola-hit communities in DR Congo

A safer, more dignified journey for all migrants, tops agenda at global conference in Marrakech

Following week of bloodshed, ‘suffering of the Afghan people must end’: UN mission chief

Coronavirus: European Commission calls for action in protecting seasonal workers

EU Commission closer to imposing anti-dumping duties on Chinese solar panel imports?

Soil pollution ‘jeopardizing’ life on Earth, UN agency warns on World Day

A shocking new report reveals what we’ve done to the natural world

Education should be like everything else. An on-demand service

These photos show some of the world’s smallest things massively magnified

Federalist EU ‘naively’ believes Washington shares her TTIP high fever

Taxation: Commission refers Spain to the Court for imposing disproportionate sanctions for failure to report assets held abroad

Making the most of our ‘extra time’ – for ourselves and society

What young people can teach world leaders about mental health in 2020

Quicker freezing and confiscation of criminal assets to fight organised crime

Guatemala Dos Erres massacre conviction welcomed by UN human rights office

How COVID-19 might help us win the fight against climate change

Afghan refugees: €21 million in humanitarian aid for host communities and vulnerable populations in Pakistan and Iran

Cultural tolerance is a must: “No sir, I’m not inferior!”

UN investigates systematic sexual violence across South Sudan

Technological innovation can bolster trust and security at international borders. Here’s how

The role of employers in the post #MeToo era

How COVID-19 revealed 3 critical AI procurement blindspots that could put lives at risk

5 ways to fast-track the transition to a carbon neutral world

Anxious gorillas, thirsty koalas and lame cows – how climate change is making animals miserable

Resisting EU budget cuts

COP21 Breaking News_10 December: the final sprint of the Final Agreement Negotiations

Canada grants asylum for Saudi teen who fled family: UNHCR

MEPs oppose EU Commission plans to authorise three herbicide-resistant GMOs

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s